NEW YORK, March 13, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Quest Diagnostics Incorporated (NYSE: DGX), Life Technologies Corporation (NASDAQ: LIFE), Laboratory Corporation of America Holdings (NYSE: LH), Health Net, Inc. (NYSE: HNT), and CombiMatrix Corporation (NASDAQ: CBMX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Quest Diagnostics Incorporated Research Report
In the recently held HIMSS 2013 Conference, Quest Diagnostics presented its award-winning healthcare information technology (HIT) connectivity solutions. The company is known for offering the broadest access to diagnostic information services through its network of laboratories and through its HIT network. Quest Diagnostics' HIT connectivity solutions support multiple healthcare stakeholders, integrate platforms, and optimize workflows strategically across health systems. Continuing to provide groundbreaking solutions, the company has been recognized in FORTUNE magazine's World's Most Admired Companies list as the No. 1 company under the "Pharmacy and Other Services" category. The Full Research Report on Quest Diagnostics Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/6bc0_DGX]
Life Technologies Corporation Research Report
Under a collaborative agreement and related license with Harvard University, Life Technologies acquired exclusive rights to develop a panel of characterization tests designed to evaluate hPS cells for their use in a variety of discovery and translational research applications. The license expands Life Technologies' portfolio of stem cell research products and deepens its commitment to customers in the field. Considered a growing segment in the field, the global stem cell characterization market is currently estimated to be $30 million annually. The overall market for stem cell research tools is approximately $1 billion. The Full Research Report on Life Technologies Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/cd9d_LIFE]
Laboratory Corporation of America Holdings Research Report
Complimenting diseased focused approach to diagnostic testing, LabCorp launched its clinical next generation sequencing test, GeneSeq: Cardio for genetic causes of familial cardiac disease. GeneSeq: Cardio complements the company's broad testing menu and enhanced reporting for cardiovascular disease. This sequencing test is considered to be a significant milestone for the company as LabCorp embraces new technologies and bioinformatics to further its ability to service patients and physicians. For 2013 LabCorp expects revenue growth of around two to three percent, and operating cash flow of $870 million to $900 million. The Full Research Report on Laboratory Corporation of America Holdings - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/96dc_LH]
Health Net, Inc. Research Report
Health Net Foundation, the charitable foundation of Health Net, is awarding $150,000 in total grants to Northeast Valley Health Corporation for the launch of Project CARES, a new in-home care program in Los Angeles County. The grant is expected to enhance delivery of healthcare services, enabling healthcare providers to expand their reach and their services to focus more in the medically underserved residents of the community. On March 13, Health Net is set to present at the Barclays Healthcare Conference. The Full Research Report on Health Net, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/b9f6_HNT]
CombiMatrix Corporation Research Report
As of March 11, CombiMatrix went up 30.72 percent on 2.1 million shares traded. The molecular diagnostics company's 2012 revenue increased to $5.4 million, up 15 percent from the previous year. Revenue from the company's core prenatal testing markets grew by more than 101 percent over the comparable prior year, driven by a 171 percent increase in billable test volumes year-over-year. The momentum is expected to continue in 2013, as CombiMatrix continues to refine its selling organization and approach to take advantage of the prenatal market opportunity. The de-emphasized oncology business segment is also expected to stabilize, allowing for strong year-over-year top line growth. The Full Research Report on CombiMatrix Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/4e57_CBMX]
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers